Good work. And yes, you see this increase in full book provision at end of FY across many lenders. Your interpretation of $6+$6mio is fair I think. On the debt side, I am of 2 minds. As stated before, if they can resume growth, then this financing is not bad leverage. Having said that, there is a question of right-sizing that leverage. Plenti and Wisr have $25mio for comparable loan book size. So it looks like they are the outlier. My guess is that they first need to demonstrate they can resume growth, at current settings and leverage. If they do, the SP will improve substantially. They can then do another CR to deleverage. The alternative is what you have been suggesting, use the net income to repay debt/reduce leverage. Curious to see which path they choose.
- Forums
- ASX - By Stock
- MME
- Ann: FY23 Full Year Results Announcement
Ann: FY23 Full Year Results Announcement, page-4
Featured News
Add MME (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
0.010(9.09%) |
Mkt cap ! $96.00M |
Open | High | Low | Value | Volume |
11.0¢ | 12.0¢ | 11.0¢ | $36.07K | 313.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6371 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 159547 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6371 | 0.115 |
16 | 1682189 | 0.110 |
12 | 801685 | 0.105 |
14 | 607848 | 0.100 |
4 | 38000 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 159547 | 4 |
0.125 | 157240 | 5 |
0.130 | 225000 | 2 |
0.135 | 57391 | 2 |
0.140 | 395969 | 3 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
MME (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online